Live Analyst Rating Changes 2092 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Alec Stranahan
BofA
Alec Stranahan
Bank of America Securities
Wall Street Analyst
★★★☆☆
#1509
on 13Foresight · ranked by our own returns
49%
Success Rate
-0.2%
Average Return
19 of 39 calls profitable · -4.6% vs benchmark
📈 Across the calls we could measure, roughly 49% of Alec Stranahan's ratings turned a profit when each position was held for 1 year — averaging -0.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

184 Buy 47 Hold 71 Sell
Alec's Stock Coverage 34 ratings · 2026-06-23
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
MRNA
Moderna
 Jun 16, 2026 SELL Hold
+15.8% avg upside
38 analysts
$34.00
42.97% Downside
 -15.4%
NTLA
Intellia Therapeutics
 Jun 15, 2026 HOLD Buy
+150.1% avg upside
37 analysts
$19.00
17.60% Upside
 ·
AGIO
Agios Pharma
 Jun 15, 2026 BUY Strong Buy
+69.5% avg upside
29 analysts
$40.00
12.85% Upside
 ·
AVTX
Avalo Therapeutics
 Jun 12, 2026 BUY Strong Buy
+229.5% avg upside
19 analysts
$35.00
117.70% Upside
 ·
CRBU
Caribou Biosciences
 Jun 11, 2026 BUY Strong Buy
+579.9% avg upside
12 analysts
$6.00
257.04% Upside
 ·
RVMD
Revolution Medicines
 Jun 08, 2026 BUY Strong Buy
-13.2% avg upside
32 analysts
$185.00
11.58% Upside
 +9.8%
ERAS
Erasca
 Jun 08, 2026 HOLD Strong Buy
+30.2% avg upside
14 analysts
$16.00
10.50% Upside
 +8.6%
TGTX
TG Therapeutics
 Jun 04, 2026 SELL Strong Buy
-31.5% avg upside
19 analysts
$17.00
69.64% Downside
 -35.0%
HCM
HUTCHMED
 May 31, 2026 BUY Strong Buy
+214.6% avg upside
9 analysts
$20.00
96.30% Upside
 -4.8%
AKTS
Aktis Oncology, Inc.
 May 31, 2026 BUY Strong Buy
+28.5% avg upside
8 analysts
$34.00
38.30% Upside
 ·
CADL
Candel Therapeutics
 May 31, 2026 HOLD Strong Buy
+98.9% avg upside
10 analysts
$9.00
1.23% Upside
 +2.5%
IMTX
Immatics
 May 31, 2026 BUY Strong Buy
+85.9% avg upside
15 analysts
$17.00
69.17% Upside
 ·
KRYS
Krystal Biotech
 May 31, 2026 BUY Strong Buy
-27.8% avg upside
19 analysts
$364.00
3.41% Upside
 +16.8%
CATX
Perspective Therapeutics
 May 31, 2026 HOLD Strong Buy
+270.9% avg upside
22 analysts
$6.00
93.60% Upside
 -20.0%
VIR
Vir Biotechnology
 May 29, 2026 BUY Strong Buy
+177.3% avg upside
16 analysts
$16.00
68.32% Upside
 -2.5%
CGON
CG Oncology, Inc.
 May 26, 2026 BUY Strong Buy
+33.6% avg upside
17 analysts
$87.00
36.20% Upside
 +7.0%
RGNX
RegenXBio
 May 14, 2026 BUY Strong Buy
+341.8% avg upside
22 analysts
$14.00
56.49% Upside
 -8.3%
XNCR
Xencor
 May 13, 2026 HOLD Strong Buy
+144.9% avg upside
27 analysts
$17.00
25.32% Upside
 -9.0%
RXRX
Recursion Pharmaceuticals
 May 13, 2026 HOLD Buy
+146.7% avg upside
12 analysts
$6.00
84.11% Upside
 +2.0%
CRSP
Crispr Therapeutics AG
 May 13, 2026 BUY Buy
+38.2% avg upside
41 analysts
$83.00
49.02% Upside
 +2.3%
SANA
Sana Biotechnology
 May 12, 2026 BUY Strong Buy
+201.9% avg upside
14 analysts
$7.00
102.36% Upside
 +2.8%
BEAM
Beam Therapeutics
 May 12, 2026 BUY Strong Buy
+46.3% avg upside
25 analysts
$47.00
29.58% Upside
 +8.1%
JANX
Janux Therapeutics Inc
 May 08, 2026 BUY Strong Buy
+215.0% avg upside
21 analysts
$21.00
43.45% Upside
 -0.2%
EDIT
Editas Medicine
 May 07, 2026 SELL Buy
+392.7% avg upside
33 analysts
 — +12.7%
ALEC
Alector
 Apr 30, 2026 SELL Buy
+519.9% avg upside
14 analysts
 — +8.9%
WVE
Wave Life Sciences
 Apr 28, 2026 BUY Strong Buy
+259.3% avg upside
28 analysts
$19.00
204.39% Upside
 -18.1%
NVAX
Novavax
 Apr 08, 2026 SELL Hold
+155.2% avg upside
20 analysts
$8.00
12.94% Downside
 -8.4%
BTAI
Bioxcel Therapeutics
 Mar 27, 2026 SELL Buy
+1776.9% avg upside
12 analysts
$1.00
21.35% Downside
 +4.0%
MGTX
Meiragtx Holdings
 Mar 26, 2026 BUY Strong Buy
+128.3% avg upside
13 analysts
$16.00
39.87% Upside
 +50.3%
REGN
Regeneron
 Dec 10, 2024 SELL Strong Buy
+26.8% avg upside
57 analysts
$565.00
5.82% Downside
 +6.2%
LLY
Eli Lilly & Co
 Nov 01, 2024 BUY Buy
-10.5% avg upside
47 analysts
$1100.00
0.03% Upside
 +6.2%
DMRA
Damora Therapeutics
 Aug 15, 2023 BUY Strong Buy
+15.6% avg upside
19 analysts
$5.00
78.55% Downside
 ·
NXTC
NextCure
 Dec 02, 2022 SELL Strong Buy
+909.8% avg upside
10 analysts
$1.00
47.63% Downside
 +14.9%
ESPR
Esperion
 Jan 15, 2021 HOLD Buy
+699.5% avg upside
22 analysts
$35.00
1009.27% Upside
 -84.6%
🔒 29 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Alec Stranahan — Frequently Asked Questions
How accurate are Alec Stranahan's stock ratings?
Based on the calls 13Foresight could measure, about 49% of Alec's ratings were profitable over a one-year hold, with an average return of -0.2% per rating, or -4.6% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Alec ranked on 13Foresight?
Alec Stranahan is currently ranked #1509 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Alec cover?
Alec most recently has ratings on MRNA, NTLA, AGIO, AVTX, CRBU, RVMD, ERAS, TGTX, HCM, AKTS, CADL, IMTX and 22 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.